多发性骨髓瘤治疗模式与结局的种族差异:SEER-Medicare分析
该研究基于SEER-Medicare数据库(2007-2013)纳入3504例白人、858例非裔美国人和468例西班牙裔多发性骨髓瘤患者,评估治疗模式与结局的种族差异。非裔和西班牙裔患者从诊断到启动新药治疗的中位时间均长于白人,非裔患者骨髓瘤特异性生存更长,但西班牙裔患者接受自体干细胞移植的比例低于白人。
要点
- 非裔和西班牙裔患者启动新药治疗的中位时间分别为5.2和4.6个月,长于白人的2.7个月。
- 非裔患者中位骨髓瘤特异性生存为5.4年,显著长于白人的4.5年。
- 西班牙裔患者接受自体干细胞移植的比例低于白人,且移植率未随诊断年份上升。
核心结论
- 不同种族/民族的多发性骨髓瘤患者在新药治疗和自体干细胞移植使用上存在显著差异。
- 尽管总生存相似,非裔和西班牙裔患者可能未充分受益于新药治疗,因其启动治疗晚于白人。
研究设计与样本
- 基于SEER-Medicare数据库(2007-2013)的回顾性队列研究,纳入3504例白人、858例非裔美国人和468例西班牙裔多发性骨髓瘤患者。
- 要求诊断前6个月(基线)和诊断后连续参加Medicare保险,除非发生死亡。
主要发现
- 非裔和西班牙裔患者从诊断到启动新药治疗的中位时间分别为5.2和4.6个月,长于白人的2.7个月。
- 所有队列在诊断后6个月内启动新药治疗的趋势均增加,尤其是白人(所有P < .05)。
- 非裔患者中位骨髓瘤特异性生存为5.4年,显著长于白人的4.5年(P < .05);西班牙裔与白人相当。
- 中位总生存总体相似(2.6-2.8年)。
- 诊断后1年内自体干细胞移植率在白人和非裔中上升(P < .05),但西班牙裔未上升,且西班牙裔接受移植的可能性低于白人。
临床怎么用
- 临床应关注非裔和西班牙裔多发性骨髓瘤患者启动新药治疗延迟的问题,并探索减少延迟的策略。
- 对于西班牙裔患者,需关注其自体干细胞移植可及性较低的情况,评估移植转诊障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of the study was to assess racial disparities in the treatment and outcomes among white, African American, and Hispanic patients with multiple myeloma (MM). Patients with an MM diagnosis from the Surveillance Epidemiology and End Results (SEER)-Medicare (2007-2013) database were included. Continuous Medicare enrollment for 6 months before (baseline) and after MM diagnosis was required unless death occurred. Time from MM diagnosis to novel therapy initiation and autologous stem cell transplant (ASCT), overall survival (OS), and MM-specific survival (MSS) was evaluated. Unadjusted and multivariable regressions compared African Americans and Hispanics vs whites. Trends of novel therapy and ASCT use across MM diagnosis years were assessed using linear regression models. The study included 3504 whites, 858 African Americans, and 468 Hispanics. African Americans and Hispanics had a longer time from MM diagnosis to novel therapy initiation vs whites (median: 5.2 and 4.6 vs 2.7 months, respectively). All cohorts had an increasing trend of novel therapy initiation within 6 months of MM diagnosis, particularly whites (all P < .05). Median MSS was significantly longer for African Americans (5.4 years) than whites (4.5 years; P < .05), and was comparable for Hispanics and whites. Median OS was similar overall (2.6-2.8 years). ASCT rate within 1 year of MM diagnosis rose among whites and African Americans (P < .05), but not Hispanics, who were less likely to receive ASCT vs whites. Significant variations in novel therapy and ASCT use were observed among different racial/ethnic groups with MM. Although OS was similar, both African Americans and Hispanics may not be fully benefitting from the introduction of novel therapies, as they receive them later than whites.
引用
- Ailawadhi S, Parikh K, Abouzaid S, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019. PMID: 31648322. doi:10.1182/bloodadvances.2019000308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。